|
Recent Developments |
|
11-FEB-19
Glenmark Pharmaceuticals Inc., USA (Glenmark) has been granted final approval by the United States Food & Drug Administration (U.S. FDA) for Sevelamer Hydrochloride Tablets, 400 mg and 800 mg, a generic version of Renagel Tablets, 400 mg and 800 mg, of Genzyme Corporation.
07-FEB-19
Glenmark Pharmaceuticals Inc., USA (Glenmark) has been granted tentative approval by the United States Food & Drug Administration (U.S. FDA) for Fulvestr... More.. |
| Business Profile |
Future Plans |
|
|
|
|
One To One
|
|
Recent news
|
|
|
| Period ending (months) | 31-Dec-2017(9) | 31-Mar-2017(12) | 31-Mar-2016(12) | | Net sales | 47641.39 | 80093.26 | 62173.17 | | Other Income | 1361.24 | 1482.39 | 966.15 | | Total Income | 49002.63 | 81575.65 | 63139.32 | | Cost of goods sold | 38871.22 | 52997.01 | 48258.20 | | OPBDIT | 10131.41 | 28578.64 | 14881.12 | | PAT | 7928.33 | 21429.97 | 13114.65 | | Gross Block | - | - | - | | Equity capital | - | - | 282.16 | | EPS (Rs.) | - | - | - | | DPS (Rs.) | - | - | - | | BV (Rs.) | - | - | - | | P/E range (x) | - | - | - | | Debt / Equity (x) | - | - | - | | Operating margin (% of OI) | 20.7 | 35.0 | 23.6 | | Net margin (% of OI) | 16.2 | 26.3 | 20.8 |
|
|
Detailed Financials
|
|
|
|
|
